Nasdaq, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bearish -20

SCWorx Receives Nasdaq Hearings Panel Decision Granting the Company's Request to Continue its Listing on the Nasdaq Stock Market, Subject to Compliance Conditions

AI-generated analysis

πŸ“… SCWorx received a conditional decision from the Nasdaq Hearings Panel to continue its stock listing as of June 23, 2026.

⚠️ Trading was suspended in April 2026 because the share price fell below the $1.00 minimum bid price requirement.

πŸ”„ The company must obtain shareholder approval for a reverse stock split by July 22, 2026.

πŸ“‰ A reverse stock split must be executed on or before August 3, 2026.

πŸ’° Compliance with the $1.00 bid price rule must be demonstrated via 20 consecutive days of trading by August 28, 2026.

πŸ›οΈ Delisting from Nasdaq will occur if conditions are not met by the specified deadlines.

πŸ“Š Pending reinstatement, SCWorx is authorized to quote its stock on the OTCQB Market.

🀝 CEO Tim Hannibal emphasized that maintaining the Nasdaq listing remains a strategic priority for the company.

πŸš€ The company aims to expand customer relationships and advance its healthcare data management platform using AI.

Bullish Signals
  • SCWorx has successfully secured a conditional continuation of its Nasdaq listing, avoiding immediate delisting.
  • The company has received approval from OTC Markets to quote its stock on the OTCQB Market while working toward reinstatement.
  • CEO Tim Hannibal confirmed that maintaining the Nasdaq listing is a strategic priority for the organization.
Risk Factors
  • Trading remains suspended until SCWorx satisfies all Nasdaq compliance conditions by the August 2026 deadlines.
  • If the company fails to meet the reverse stock split or bid price requirements, its stock will be delisted from Nasdaq and remain on the OTC Markets.
  • The Nasdaq Listing and Hearing Review Council retains the right to review and potentially reverse the Panel's decision within 45 days.
  • SCWorx faces significant pressure to achieve a $1.00 closing price for 20 consecutive days, which may be challenging given the illiquidity of OTC Markets.
Full Analysis
SCWorx Corp. announced on June 23, 2026, that the Nasdaq Hearings Panel has granted its request to continue listing its common stock, contingent upon meeting specific compliance conditions. The company's trading was previously suspended in April 2026 due to failing the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). To regain full trading status on Nasdaq, SCWorx must secure shareholder approval for a reverse stock split by July 22, 2026, followed by the execution of the split by August 3, 2026. Finally, the company must demonstrate compliance with the bid price rule by maintaining a closing price at or above $1.00 for 20 consecutive trading days by August 28, 2026. Failure to meet these deadlines will result in delisting from Nasdaq and continued quotation on the OTC Markets. Pending reinstatement, SCWorx has received approval to quote its stock on the OTCQB Market. CEO Tim Hannibal stated that maintaining the Nasdaq listing is a strategic priority as the company focuses on expanding customer relationships and advancing its healthcare supply chain data platform.